利奈唑胺限制政策、耐药与死亡率:耐万古霉素肠球菌的准实验研究
该研究利用两家学术医学中心2008至2019年521,493例次住院数据,采用准实验倍差法评估利奈唑胺限制政策的效果。限制政策与利奈唑胺使用量下降27%、耐药率下降41%相关,总体死亡率未增加,但VRE筛查阳性患者死亡率升高4.7个百分点。作者建议结合筛查信息设置保障措施,以维护高危患者的及时治疗。
要点
- 利奈唑胺限制与使用量降27%、耐药率降41%相关,总体死亡率未增加。
- VRE筛查阳性患者死亡率升高4.7个百分点,菌血症或脓毒症者增幅更大。
- 限制政策宜结合VRE筛查设置保障措施,确保高危患者及时用药。
核心结论
- 利奈唑胺限制政策可降低抗生素使用和耐药,但可能对VRE筛查阳性高危患者造成死亡率增加,需筛查-informed safeguards。
研究设计与样本
- 准实验倍差法研究,使用两家学术医学中心2008至2019年521,493例次住院的电子健康记录数据,医院1实施限制政策,医院2为对照。
主要发现
- 利奈唑胺使用率为2.3%的住院例次,1.2%的肠球菌分离株对利奈唑胺耐药。
- 限制政策与利奈唑胺使用量减少27%(-0.9个百分点;95%CI -1.1至-0.7;P<.001)相关。
- 限制政策与利奈唑胺耐药减少41%(-1.0个百分点;95%CI -1.6至-0.4;P=.003)相关。
- 总体死亡率未增加,但VRE筛查阳性患者死亡率增加4.7个百分点(95%CI 1.9至7.5;P<.001),菌血症或脓毒症者增幅更大。
- 审批率先下降,随后利奈唑胺申请减少。
临床怎么用
- 实施利奈唑胺限制政策时应结合VRE筛查结果,对筛查阳性尤其菌血症或脓毒症高危患者保留及时用药通道。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibiotic restriction policies are intended to curb resistance, but their effects on resistance, timely treatment, and patient outcomes remain uncertain. We evaluated linezolid restrictions and whether vancomycin-resistant Enterococcus (VRE) screening identifies patients most likely to benefit. METHODS: We conducted a quasi-experimental difference-in-differences study using electronic health record data from 521,493 admissions at 2 academic medical centers from 2008 through 2019. Hospital 1 introduced a formal prior-authorization pager system in 2011 and stricter linezolid-specific criteria with enhanced post-prescription review in 2014; Hospital 2 served as a control. Outcomes included linezolid use, linezolid-resistant Enterococcus isolates, in-hospital mortality overall and by VRE status, and stewardship request behavior. RESULTS: Linezolid was used in 2.3% of admissions; 1.2% of Enterococcus isolates were linezolid resistant. Restriction policies were associated with a 27% reduction in linezolid use (-0.9 percentage points; 95% confidence interval, -1.1 to -0.7; P < .001) and a 41% reduction in resistance (-1.0 percentage points; 95% confidence interval, -1.6 to -0.4; P = .003). Overall mortality did not increase, but mortality among VRE-screen-positive patients increased by 4.7 percentage points (95% confidence interval, 1.9 to 7.5; P < .001), with larger increases among those with bacteremia or sepsis. Approval rates declined first, followed by fewer linezolid requests. CONCLUSIONS: Restriction policies can reduce antibiotic use and resistance but may benefit from screening-informed safeguards to preserve timely treatment for high-risk patients.
引用
- Kong EL, Kubiak DW, Shenoy ES, et al. Antibiotic Stewardship, Resistance, and Mortality in Vancomycin-Resistant Enterococcus: A Quasi-Experimental Study of Linezolid Restrictions. Clin Infect Dis. 2026. PMID: 42880747. doi:10.1093/cid/ciag656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。